TNF and rheumatoid arthritis: Recently, the ORAL Surveillance trial provided important data on the comparative safety of tofacitinib and tumor necrosis factor (TNF) inhibitors (TNFis) in the treatment of RA, raising concerns about the occurrence of malignancies and major adverse cardiovascular events (MACEs) during JAKi treatment (8).